Literature DB >> 16909242

Secondary failure of plasma therapy in factor H deficiency.

Sylvie Nathanson1, Tim Ulinski, Véronique Frémeaux-Bacchi, Georges Deschênes.   

Abstract

We report a patient with homozygous factor H deficiency leading to permanent alternate complement activation and early onset of the hemolytic uremic syndrome. He was successfully treated with weekly infusions of fresh frozen plasma over 4 years, displaying normal blood pressure while only treated with an angiotensin converting enzyme (ACE) inhibitor, a steady level of haptoglobin, low-range proteinuria and normal creatinine clearance. By the end of the fourth year of treatment, he dramatically developed a relapse of hemolytic and uremic syndrome, displaying undetectable haptoglobin, nephrotic range proteinuria and progressive renal failure. Despite a ten-fold increase in the dosage of plasma infusion through daily plasma exchange, haptoglobin remained undetectable while circulating antigenic factor H levels reached 22-24% (normal values 65-140%). Three months following the biological onset of the relapse, a bilateral nephrectomy was performed owing to uncontrolled hypertension and rapidly progressive renal failure. The molecular mechanism of plasma resistance remained unclear while antifactor H antibodies were not detected in the plasma. We suggest that protracted administration of exogenous factor H might not be a long-term strategy in homozygous factor H deficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16909242     DOI: 10.1007/s00467-006-0237-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

1.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Chantal Loirat; Sylvie Cloarec; Marie-Alice Macher; Jacques Blouin; Hubert Nivet; Laurence Weiss; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

2.  Familial hemolytic uremic syndrome associated with complement factor H deficiency.

Authors:  D Landau; H Shalev; G Levy-Finer; A Polonsky; Y Segev; L Katchko
Journal:  J Pediatr       Date:  2001-03       Impact factor: 4.406

3.  Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.

Authors:  S Nathanson; V Frémeaux-Bacchi; G Deschênes
Journal:  Pediatr Nephrol       Date:  2001-07       Impact factor: 3.714

4.  Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.

Authors:  Christoph Licht; Annic Weyersberg; Stefan Heinen; Ludwig Stapenhorst; Jacqueline Devenge; Bodo Beck; Ruediger Waldherr; Michael Kirschfink; Peter F Zipfel; Bernd Hoppe
Journal:  Am J Kidney Dis       Date:  2005-02       Impact factor: 8.860

5.  Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene.

Authors:  Hiroaki Nishimatsu; Yasunobu Hirata; Takayuki Shindo; Hiroki Kurihara; Masao Kakoki; Daisuke Nagata; Hiroshi Hayakawa; Hiroshi Satonaka; Masataka Sata; Akihiro Tojo; Etsu Suzuki; Kenji Kangawa; Hisayuki Matsuo; Tadaichi Kitamura; Ryozo Nagai
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

6.  Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene.

Authors:  T Shindo; Y Kurihara; H Nishimatsu; N Moriyama; M Kakoki; Y Wang; Y Imai; A Ebihara; T Kuwaki; K H Ju; N Minamino; K Kangawa; T Ishikawa; M Fukuda; Y Akimoto; H Kawakami; T Imai; H Morita; Y Yazaki; R Nagai; Y Hirata; H Kurihara
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

7.  Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases.

Authors:  Marie-Agnès Dragon-Durey; Véronique Frémeaux-Bacchi; Chantal Loirat; Jacques Blouin; Patrick Niaudet; Georges Deschenes; Paul Coppo; Wolf Herman Fridman; Laurence Weiss
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

8.  Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H.

Authors:  M Ohali; H Shalev; M Schlesinger; Y Katz; L Kachko; R Carmi; S Sofer; D Landau
Journal:  Pediatr Nephrol       Date:  1998-10       Impact factor: 3.714

  8 in total
  13 in total

1.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

2.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.

Authors:  Fadi Fakhouri; Elena Goicoechea de Jorge; Frédérique Brune; Philippe Azam; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2010-05-05       Impact factor: 10.612

3.  Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Authors:  Samhar I Al-Akash; P Stephen Almond; Van H Savell; Salam I Gharaybeh; Cris Hogue
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

4.  Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Lapeyraque; Véronique Frémeaux-Bacchi; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2010-12-15       Impact factor: 3.714

Review 5.  aHUS caused by complement dysregulation: new therapies on the horizon.

Authors:  Aoife M Waters; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2010-06-18       Impact factor: 3.714

6.  Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations.

Authors:  Anne-Laure Lapeyraque; Eric Wagner; Véronique Phan; Marie-José Clermont; Aïcha Merouani; Véronique Frémeaux-Bacchi; Timothy H J Goodship; Pierre Robitaille
Journal:  Pediatr Nephrol       Date:  2008-04-19       Impact factor: 3.714

7.  Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options.

Authors:  Sudarsana De; Aoife M Waters; Audrey O Segal; Agnes Trautmann; Elizabeth A Harvey; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2009-10-24       Impact factor: 3.714

8.  Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences?

Authors:  Anis Larakeb; Sandrine Leroy; Véronique Frémeaux-Bacchi; Marta Montchilova; Béatrice Pelosse; Olivier Dunand; Georges Deschênes; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2007-07-10       Impact factor: 3.714

9.  Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Benjamin L Shneider; Jonathan S Bromberg; Patricia A Shi; Stephen C Ward; Margret S Magid; Corinne Benchimol; Mouin G Seikaly; Sukru H Emre; Elena Bresin; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2008-11-12       Impact factor: 8.237

Review 10.  Podocyte dysfunction in atypical haemolytic uraemic syndrome.

Authors:  Marina Noris; Caterina Mele; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2015-01-20       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.